In today’s briefing:
- AstraZeneca PLC: How Will Its Expansion In Vaccines & Cell Therapy Play Out? – Major Drivers
- Bristol-Myers Squibb Company: A Deep Dive Into The Progress Of Its Clinical Portfolio! – Major Drivers
- DexCom Inc.: Why Are We Bullish On This Med-Tech Player Despite The Highly Evident Challenges Ahead? – Major Drivers
- Edwards Lifesciences Corporation: Increased Investment in Field Resources and Patient Access Initiatives! – Major Drivers
- Gilead Sciences: Acquisition of CymaBay Therapeutics Enhancing Liver Disease Portfolio & 6 Major Drivers
AstraZeneca PLC: How Will Its Expansion In Vaccines & Cell Therapy Play Out? – Major Drivers
- Based on the Q1 2024 results earnings call for AstraZeneca, the British multinational pharmaceutical and biopharmaceutical company seems to be on a steady growth trajectory, but like all corporations, it’s not without its risks.
- In terms of its achievements, AstraZeneca reported its first quarter of 2024 with a 19% growth in total revenue, reflecting high demand for its products.
- Core earnings per share rose by 13%.
Bristol-Myers Squibb Company: A Deep Dive Into The Progress Of Its Clinical Portfolio! – Major Drivers
- It is clear from Bristol-Myers Squibb’s first quarter 2024 earnings that the company has had a strong start to the year, even as it navigates some challenges.
- The firm’s performance during this time showcased the strength and potential of its commercial portfolio and the progress it has made in advancing its pipeline.
- Key brands such as Eliquis, Opdualag, Reblozyl, Yervoy, and Breyanzi have demonstrated significant strength, contributing to the company’s overall performance.
DexCom Inc.: Why Are We Bullish On This Med-Tech Player Despite The Highly Evident Challenges Ahead? – Major Drivers
- Dexcom, Inc., particularly known for its continuous glucose monitoring (CGM) technology, consistently showcased strong performance in the first quarter of 2024 with an organic revenue growth of 25% compared to the first quarter of 2023.
- This noteworthy surge is credited to the substantial demand for Dexcom CGM, seen as customers increasingly value its leading product performance and unique user experience.
- The shift towards Dexcom’s CGM technology has been significant, especially since the launch of G7 in the U.S., which enabled Dexcom to attract a broad range of new prescribers and improve its impact within primary care, resulting in growing demand from people with diabetes.
Edwards Lifesciences Corporation: Increased Investment in Field Resources and Patient Access Initiatives! – Major Drivers
- Edwards Lifesciences Corporation recorded robust first quarter 2024 results, demonstrating growth on numerous fronts.
- The company’s total sales rose by 10% to $1.6 billion against the same period last year, leading Edwards to raise its 2024 sales guidance to the high end of 8% to 10%.
- This highlights the company’s successful strategic direction, underscored by its substantial investments across transcatheter platforms which are addressing patient needs associated with aortic, mitral, and tricuspid diseases.
Gilead Sciences: Acquisition of CymaBay Therapeutics Enhancing Liver Disease Portfolio & 6 Major Drivers
- Gilead Sciences Inc. reported a solid first quarter of 2024.
- Total product sales, exclusive of Veklury, rose 6% year-over-year to $6.1 billion.
- Growth was driven primarily by demand across its HIV, oncology, and liver disease verticals.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
